A Phase 2 interventional study of Mosunetuzumab and Polatuzumab vedotin in Lymphoma, Follicular and Follicular Lymphoma, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing mosunetuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 3 of them phase 3. mosunetuzumab · Lymphoma, Follicular.
Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, this one is the 11th largest by enrollment, is one of 6 that started in 2022, is one of 11 in phase 2, reaches primary completion later than 0 of the 14 other live ones, and was the 7th registered.
1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →8 of the 17 studies testing mosunetuzumab in Lymphoma, Follicular are open now, in 3 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Oslo University Hospital · Sites in Finland, Norway
Ages 18+
By country, each count listing its studies:
mosunetuzumab: first FDA approval 2022 (LUNSUMIO VELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 3
First in 2020; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 42 across the 17 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
Washington University School of Medicine has 6 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
4 of the studies testing mosunetuzumab in Lymphoma, Follicular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05849857Oslo University HospitalMosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries | 2027-06 |
| NCT07031700Tianjin Medical University Cancer Institute and HospitalA Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL | 2027-06-30 |
| NCT06442475University of WashingtonLow Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma | 2027-08-12 |
| NCT04792502Brown UniversityMosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead. Polatuzumab vedotin is an antibody-drug conjugate that attaches to certain cancerous B cells and then delivers a drug specifically to those cells.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
One or more of the following criteria (adapted from GELF criteria):
Adequate hematologic and organ function (unless due to underlying lymphoma per the investigator; see below), defined as follows:
Patients with extensive bone marrow involvement by lymphoma and/or disease-related cytopenias (e.g., immune thrombocytopenia) may be enrolled if the following criteria are met:
Exclusion Criteria:
Treatment with systemic medications, including but not limited to prednisone (> 20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1.
* Note: The use of inhaled , mineralocorticoids for management of orthostatic hypotension, and single dose dexamethasone for nausea or B symptoms is permitted.
Active infection.
* Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation
Active infection.
* Patients who are positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR to be eligible for study participation
Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a will be required during the study.
* Patients must not receive live, attenuated vaccines (e.g., FluMist®) while receiving study treatment or after the last dose until B cell recovery to the normal ranges.
Other that could affect compliance with the protocol or interpretation of results, with the exception of the following:
History of autoimmune disease, including, but not limited to, myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
Pregnant or lactating or intending to become pregnant during the study.
* Women of must have 1 negative serum pregnancy test result (minimum sensitivity, 25 mIU/mL) within 7 days of initiating Cycle 1 Day 1 of therapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive CD3xCD20 bispecific antibody mosunetuzumab administered subcutaneously in combination with CD79b directed ADC polatuzumab vedotin administered intravenously. Mosunetuzumab and polatuzumab vedotin are given in combination for 6 cycles. Mosunetuzumab is given on Days 1, 8, and 15 of cycle 1 and then Day 1 thereafter, and polatuzumab vedotin is given on Day 1. After 6 cycles, patients continue on mosunetuzumab alone for 2 additional cycles. Patients undergo scans at the end of cycle 8, and if those scans show a complete response, patients will stop any further treatment and will enter follow-up. Patients with a partial response or stable disease on scans at the end of cycle 8 may receive up to 9 additional cycles of mosunetuzumab in the absence of disease progression or unacceptable toxicity. All cycles are planned to be 21 days.
Drug: Mosunetuzumab · Drug: Polatuzumab vedotin
Mosunetuzumab is administered subcutaneously using a "step-up" dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg.
Also known as: RO7030816, BTCT4465A
Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
Also known as: RO5541077, DCDS4501A
Number of Participants With Complete Response (CR) as Best Response
CR determined by response to treatment by PET-CT at end of treatment per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: Through completion of treatment (estimated to be 1 year)
Number of Participants With Complete Response (CR)
CR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Number of Participants With Partial Response (PR)
PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Number of Participants With Partial Response (PR) as Best Response
PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: Through completion of treatment (estimated to be 1 year)
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)
CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)
CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: Through completion of treatment (estimated to be 1 year)
Number of Participants With Stable Disease (SD)
SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Number of Participants With Stable Disease (SD) as Best Response
SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: Through completion of treatment (estimated to be 1 year)
Number of Participants With Progressive Disease (PD)
PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Number of Participants With Progressive Disease (PD) as Best Response
PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: Through completion of treatment (estimated to be 1 year)
Number of Participants With Complete Response (CR)
CR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Number of Participants With Partial Response (PR)
PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)
CR and PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Number of Participants With Stable Disease (SD)
SD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Number of Participants With Progressive Disease (PD)
PD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Time to First Response of Complete Response (CR) or Partial Response (PR)
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year).
Time frame: Through completion of treatment (estimated to be 1 year)
Time to First Complete Response (CR)
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)
Time frame: Through completion of treatment (estimated to be 1 year)
Frequencies and Grades of Treatment-emergent Adverse Events (TEAEs)
Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
Rate of Treatment Discontinuation Due to Treatment-emergent Adverse Events (TEAEs)
TEAEs are defined as adverse events that are possibly, probably, or definitely related to study treatment and occur on or after first dose of study treatment..
Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
Percentage of Patients Requiring Any Tocilizumab Doses for Management of Cytokine Release Syndrome (CRS)
Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.
Time frame: Up to approximately 1 year and 3 days
Number of Tocilizumab Doses Per Patient for Management of Cytokine Release Syndrome (CRS)
Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.
Time frame: Up to approximately 1 year and 3 days
Progression-free Survival (PFS)
Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.
Time frame: At 24 months
Progression-free Survival (PFS)
Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.
Time frame: At 48 months
Overall Survival (OS)
Overall survival is defined from the time from study enrollment to death from any cause.
Time frame: At 24 months
Overall Survival (OS)
Overall survival is defined from the time from study enrollment to death from any cause.
Time frame: At 48 months
Duration of First Response of Complete Response (CR) or Partial Response (PR)
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)
Time frame: Through completion of follow-up (estimated to be 6 years)
Duration of First Complete Response (CR)
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)
Time frame: Through completion of follow-up (estimated to be 6 years)
Time to Next Treatment (TTNT)
Time to next treatment (TTNT) initiation is defined as the time from study enrollment to the first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy, or immunotherapy) after completion of study treatment.
Time frame: Through completion of follow-up (estimated to be 6 years)
| Milestone | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Started | 34 |
| Completed | 29 |
| Not completed | 5 |
| Withdrew: Adverse event | 3 |
| Withdrew: Disease progression | 1 |
| Withdrew: Inadequate response post cycle 2 pet scan | 1 |
CR determined by response to treatment by PET-CT at end of treatment per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Complete Response (CR) as Best Response | 30 |
CR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Complete Response (CR) | 26 |
PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Partial Response (PR) | 2 |
PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Partial Response (PR) as Best Response | 2 |
CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR) | 28 |
CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR) | 32 |
SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Stable Disease (SD) | 0 |
SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Stable Disease (SD) as Best Response | 1 |
PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Progressive Disease (PD) | 1 |
PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Progressive Disease (PD) as Best Response | 1 |
CR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Complete Response (CR) | 20 |
PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Partial Response (PR) | 11 |
CR and PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR) | 31 |
SD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Stable Disease (SD) | 2 |
PD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Participants With Progressive Disease (PD) | 1 |
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year).
| days | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Time to First Response of Complete Response (CR) or Partial Response (PR) | 42 (42 to 43) |
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)
| days | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Time to First Complete Response (CR) | 48.5 (42 to 165) |
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Grade 1/2 Anemia | 14 |
| Grade 1/2 Eosinophilia | 1 |
| Grade 3/4/5 Febrile neutropenia | 1 |
| Grade 1/2 Ejection fraction decrease | 1 |
| Grade 1/2 Tachycardia | 2 |
| Grade 1/2 Palpitations | 1 |
| Grade 1/2 Vertigo | 2 |
| Grade 1/2 Conjunctivitis | 1 |
| Grade 1/2 Eye pain | 1 |
| Grade 1/2 Abdominal pain | 4 |
| Grade 3/4/5 Abdominal pain | 1 |
| Grade 1/2 Bloating | 2 |
| Grade 1/2 Constipation | 15 |
| Grade 3/4/5 Constipation | 1 |
| Grade 1/2 Diarrhea | 14 |
| Grade 3/4/5 Diarrhea | 3 |
| Grade 1/2 Dry mouth | 1 |
| Grade 1/2 Dyspepsia | 2 |
| Grade 1/2 Gastroesophageal reflux disease | 2 |
| Grade 1/2 GERD flare | 1 |
| Grade 1/2 Nausea | 17 |
| Grade 1/2 Vomiting | 6 |
| Grade 1/2 Chills | 4 |
| Grade 1/2 Fatigue | 18 |
| Grade 1/2 Fever | 6 |
| Grade 1/2 Bruise of L forearm at infusion site | 1 |
| Grade 1/2 Flatulence | 1 |
| Grade 1/2 Shakiness | 1 |
| Grade 1/2 Infusion related reaction | 1 |
| Grade 1/2 Infusion site extravasation | 1 |
| Grade 1/2 Injection site reaction | 24 |
| Grade 1/2 Malaise | 2 |
| Grade 1/2 Pain | 2 |
| Grade 1/2 Allergic reaction | 1 |
| Grade 1/2 Tumor flare | 1 |
| Grade 1/2 Enterocolitis infectious | 3 |
| Grade 1/2 Eye infection | 1 |
| Grade 1/2 Gallbladder infection | 1 |
| Grade 1/2 Herpes simplex reactivation | 1 |
| Grade 1/2 Rhinovirus | 1 |
| Grade 1/2 Folliculitis | 1 |
| Grade 1/2 Lung infection | 1 |
| Grade 1/2 Sinusitis | 1 |
| Grade 1/2 Skin infection | 1 |
| Grade 1/2 Upper respiratory infection | 10 |
| Grade 3/4/5 Upper respiratory infection | 1 |
| Grade 1/2 Urinary tract infection | 1 |
| Grade 1/2 Vaginal infection | 1 |
| Grade 1/2 Fall | 1 |
| Grade 1/2 Foot fracture | 1 |
| Grade 1/2 Spider bite | 1 |
| Grade 1/2 Alanine aminotransferase increased | 10 |
| Grade 1/2 Alkaline phosphatase increased | 3 |
| Grade 1/2 Aspartate aminotransferase increased | 9 |
| Grade 1/2 Blood bilirubin increased | 4 |
| Grade 1/2 Cholesterol high | 1 |
| Grade 1/2 Creatinine increased | 5 |
| Grade 1/2 Elevated TSH | 1 |
| Grade 1/2 LDH increased | 18 |
| Grade 1/2 Lymphocyte count decreased | 14 |
| Grade 3/4/5 Lymphocyte count decreased | 15 |
| Grade 1/2 Neutrophil count decreased | 6 |
| Grade 3/4/5 Neutrophil count decreased | 8 |
| Grade 1/2 Platelet count decreased | 4 |
| Grade 3/4/5 Platelet count decreased | 1 |
| Grade 1/2 Weight loss | 1 |
| Grade 1/2 White blood cell decreased | 10 |
| Grade 3/4/5 White blood cell decreased | 2 |
| Grade 1/2 Hypercalcemia | 3 |
| Grade 1/2 Hyperglycemia | 6 |
| Grade 1/2 Hyperkalemia | 8 |
| Grade 1/2 Hypernatremia | 1 |
| Grade 1/2 Hypoalbuminemia | 2 |
| Grade 1/2 Hypocalcemia | 3 |
| Grade 1/2 Hypoglycemia | 2 |
| Grade 1/2 Hypokalemia | 1 |
| Grade 1/2 Hyponatremia | 5 |
| Grade 1/2 Hypophosphatemia | 2 |
| Grade 1/2 Hyperlipidemia | 1 |
| Grade 1/2 Hyperphosphatemia | 1 |
| Grade 1/2 Arthralgia | 4 |
| Grade 1/2 Arthritis | 1 |
| Grade 1/2 Back pain | 2 |
| Grade 1/2 Bone pain | 2 |
| Grade 1/2 Generalized muscle weakness | 2 |
| Grade 1/2 Muscle weakness upper limb | 1 |
| Grade 1/2 Left shoulder pain | 1 |
| Grade 1/2 Right Achilles injury | 1 |
| Grade 1/2 Myalgia | 6 |
| Grade 3/4/5 Myelodysplastic syndrome | 1 |
| Grade 1/2 Dizziness | 1 |
| Grade 1/2 Headache | 10 |
| Grade 1/2 Peripheral motor neuropathy | 1 |
| Grade 1/2 Peripheral sensory neuropathy | 13 |
| Grade 1/2 Tremor | 3 |
| Grade 3/4/5 Vasovagal reaction | 1 |
| Grade 3/4/5 Pregnancy loss | 1 |
| Grade 1/2 Depression | 1 |
| Grade 1/2 Insomnia | 4 |
| Grade 1/2 Emotional lability | 1 |
| Grade 1/2 Mood changes | 1 |
| Grade 1/2 Hematuria | 2 |
| Grade 1/2 Proteinuria | 2 |
| Grade 1/2 Dysuria | 1 |
| Grade 1/2 Urinary frequency | 1 |
| Grade 1/2 Blood in semen | 1 |
| Grade 1/2 Allergic rhinitis | 1 |
| Grade 1/2 Cough | 6 |
| Grade 1/2 Dyspnea | 2 |
| Grade 1/2 Epistaxis | 1 |
| Grade 1/2 Hiccups | 1 |
| Grade 1/2 Hoarseness | 2 |
| Grade 1/2 Hypoxia | 1 |
| Grade 1/2 Nasal Congestion | 2 |
| Grade 1/2 Pneumonitis | 2 |
| Grade 1/2 Postnasal drip | 1 |
| Grade 1/2 Pleurisy | 1 |
| Grade 1/2 Rhinorrhea | 2 |
| Grade 1/2 Sore throat | 1 |
| Grade 1/2 Wheezing | 1 |
| Grade 1/2 Alopecia | 2 |
| Grade 1/2 Body odor | 1 |
| Grade 1/2 Dry skin | 5 |
| Grade 1/2 Pruritus | 5 |
| Grade 1/2 Rash maculo-papular | 4 |
| Grade 1/2 Poison Ivy | 1 |
| Grade 1/2 Rash | 13 |
| Grade 3/4/5 Rash | 1 |
| Grade 1/2 Skin peeling | 4 |
| Grade 1/2 Hair thinning | 2 |
| Grade 1/2 Flushing | 2 |
| Grade 1/2 Hot flashes | 1 |
| Grade 1/2 Hypertension | 1 |
| Grade 1/2 Hypotension | 5 |
| Grade 1/2 Phlebitis | 1 |
| Grade 1/2 Cytokine release syndrome | 20 |
TEAEs are defined as adverse events that are possibly, probably, or definitely related to study treatment and occur on or after first dose of study treatment..
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Rate of Treatment Discontinuation Due to Treatment-emergent Adverse Events (TEAEs) | 3 |
Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.
| Participants | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Percentage of Patients Requiring Any Tocilizumab Doses for Management of Cytokine Release Syndrome (CRS) | 1 |
Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.
| dose of tocilizumab | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Number of Tocilizumab Doses Per Patient for Management of Cytokine Release Syndrome (CRS) | 1 |
Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.
Results for this outcome have not been posted.
Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.
Results for this outcome have not been posted.
Overall survival is defined from the time from study enrollment to death from any cause.
Results for this outcome have not been posted.
Overall survival is defined from the time from study enrollment to death from any cause.
Results for this outcome have not been posted.
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)
Results for this outcome have not been posted.
Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)
Results for this outcome have not been posted.
Time to next treatment (TTNT) initiation is defined as the time from study enrollment to the first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy, or immunotherapy) after completion of study treatment.
Results for this outcome have not been posted.
Collected over Adverse events were evaluated from the start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first. Total time: Up to1 year and 30 days. All-cause mortality was assessed for median follow-up of 984 days, full range 483-1323 days. Anticipated duration is up to 6 years at final results reporting.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mosunetuzumab and Polatuzumab Vedotin | 0/34 (0%) | 11/34 (32.4%) | 34/34 (100%) |
| Event | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Cytokine release syndromeImmune system disorders | 3/34 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/34 |
| Abdominal painGastrointestinal disorders | 1/34 |
| DiarrheaGastrointestinal disorders | 1/34 |
| Infusion site extravasationGeneral disorders | 1/34 |
| Upper respiratory infectionInfections and infestations | 1/34 |
| Neutrophil count decreasedInvestigations | 1/34 |
| Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/34 |
| Pregnancy lossPregnancy, puerperium and perinatal conditions | 1/34 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/34 |
| Event | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Lymphocyte count decreasedInvestigations | 29/34 |
| Injection site reactionGeneral disorders | 24/34 |
| FatigueGeneral disorders | 18/34 |
| LDH increasedInvestigations | 18/34 |
| NauseaGastrointestinal disorders | 17/34 |
| Cytokine release syndromeImmune system disorders | 17/34 |
| ConstipationGastrointestinal disorders | 16/34 |
| DiarrheaGastrointestinal disorders | 16/34 |
| AnemiaBlood and lymphatic system disorders | 14/34 |
| RashSkin and subcutaneous tissue disorders | 14/34 |
| Age, Continuous(years) | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Mean | 63.1 (29 to 83) |
| Sex: Female, Male(Participants) | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Female | 16 |
| Male | 18 |
| Ethnicity (NIH/OMB)(Participants) | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 34 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 30 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Mosunetuzumab and Polatuzumab Vedotin |
|---|---|
| United States | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Sep 2025, 34 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 151 non-industry phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 110. This study's 34 months is below that.
Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mosunetuzumab · Polatuzumab vedotin
Washington University School of Medicine →